RxDoctor Payments Data

Man Duong, MD

Internal Medicine · Calexico, CANPI 1679718399

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 52 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$364
  • Novo Nordisk$220
  • Boehringer Ingelheim$165
  • GSK$56
  • Novartis$42
  • Otsuka America Pharmaceutical, Inc.$38
  • plus $182 from 8 others

What the payments were for

  • Food & beverage$1,066100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,066 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$643,873
Medicare patients
362
Services billed
7,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$147,110
JardianceEmpagliflozin134$101,949
FarxigaDapagliflozin Propanediol110$81,558
TrulicityDulaglutide78$72,440
JanuviaSitagliptin Phosphate101$70,621
RybelsusSemaglutide45$53,105
MyrbetriqMirabegron63$49,422
EliquisApixaban65$46,280
DapagliflozinDapagliflozin Propanediol57$44,142
DovatoDolutegravir Sodium/Lamivudine12$33,636
XareltoRivaroxaban37$33,001
Diclofenac Sodium212$31,426
EntrestoSacubitril/Valsartan32$30,879
Xigduo XrDapaglifloz Propaned/Metformin25$22,482
NamzaricMemantine Hcl/Donepezil Hcl22$19,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$220$200,214208 claims
Boehringer IngelheimJardiance, Tradjenta$165$118,293167 claims
AstraZenecaFarxiga, Breztri Aerosphere$364$93,129130 claims
MerckJanuvia, Janumet$16$75,244112 claims
Lilly USA, LLCTrulicity$35$72,44078 claims
NovartisEntresto$42$30,87932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Calexico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →